Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile

Open access

Published version of a preprint

Abstract

Background: Weight loss therapy is becoming more and more important, and two classes of molecules, namely amylin receptor and GLP-1 receptor agonists, have shown promise in this regard. Interestingly, these molecules have several overlapping pharmacological effects, such as suppression of gastric emptying, reduction of glucagon secretion and weight loss in common; however, they also have distinct effects on prandial insulin secretion. Hence, a combination of these two mechanisms is of significant interest. Methods: In this study, we investigated the add-on potential of the dual amylin and calcitonin receptor agonist (DACRA) KBP-089 in combination with the GLP-1 receptor agonist liraglutide as obesity treatment in high-fat diet (HFD) fed rats. Results: Increasing doses of KBP-089 and liraglutide alone and in combination were studied with respect to their effects on body weight, food intake and glucose metabolism during a 9-week intervention study conducted in HFD rats. Further, the gastric emptying rate during an oral glucose tolerance was assessed. Treatment with KBP-089 and liraglutide dose-dependently lowered body weight 15% (at 2.5 μg/kg/day) and 7% (at 400 μg/kg/day) in HFD rats, respectively, while the combination resulted in a 21% body weight reduction, which was mirrored by reduction in fat depot sizes. Gastric emptying and glucose metabolism were improved, primarily by KBP-089, although liraglutide led to a reduction in fasting plasma glucagon. Conclusion: DACRAs complement GLP-1 on food intake, body weight, and glucose tolerance indicating the potential for an add-on therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12902-020-00678-2

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Accumulated food intake for the initial 7 days (a) and for the entire duration of the study (b). Body weights at study end (c). Calculated food efficiency (d). N = 8–10 rats per group. Statistical analysis between groups were performed as a one-way ANOVA followed by Tukey’s post-hoc test with the following annotations: *P < 0.05, **P < 0.01, ***P < 0.001 vs. vehicle, #P < 0.05, ##P < 0.01 vs. liraglutide (200 μg/kg), §P < 0.05, §§P < 0.01 vs. liraglutide (400 μg/kg), ¤ P < 0.05, ¤¤ P < 0.01, ¤¤¤ P < 0.001 vs. KBP-089 (0.625 μg/kg), † P < 0.05, †† P < 0.01, ††† P < 0.001 vs. KBP-089 (1.25 μg/kg) and ‡‡P < 0.01 vs. KBP-089 (2.5 μg/kg). All data are means ± SEM
Fig. 1 Accumulated food intake for the initial 7 days (a) and for the entire duration of the study (b). Body weights at study end (c). Calculated food efficiency (d). N = 8–10 rats per group. Statistical analysis between groups were performed as a one-way ANOVA followed by Tukey’s post-hoc test with the following annotations: *P < 0.05, **P < 0.01, ***P < 0.001 vs. vehicle, #P < 0.05, ##P < 0.01 vs. liraglutide (200 μg/kg), §P < 0.05, §§P < 0.01 vs. liraglutide (400 μg/kg), ¤ P < 0.05, ¤¤ P < 0.01, ¤¤¤ P < 0.001 vs. KBP-089 (0.625 μg/kg), † P < 0.05, †† P < 0.01, ††† P < 0.001 vs. KBP-089 (1.25 μg/kg) and ‡‡P < 0.01 vs. KBP-089 (2.5 μg/kg). All data are means ± SEMCC BY · PubMed Central
Fig. 2 Weights of epididymal (a), inguinal (b) and perirenal (c) white adipose tissue (AT) at study end (n = 8–10 rats per group). Statistical analysis between groups (a and b) were performed as a one-way ANONA followed by Tukey’s post-hoc test and as Kruskal Wallis test followed by Dunn’s post-hoc test with the following annotations: *P < 0.05, **P < 0.01, ***P < 0.001 vs. vehicle, §P < 0.05, §§P < 0.01 vs. liraglutide (400 μg/kg). All data are means ± SEM
Fig. 2 Weights of epididymal (a), inguinal (b) and perirenal (c) white adipose tissue (AT) at study end (n = 8–10 rats per group). Statistical analysis between groups (a and b) were performed as a one-way ANONA followed by Tukey’s post-hoc test and as Kruskal Wallis test followed by Dunn’s post-hoc test with the following annotations: *P < 0.05, **P < 0.01, ***P < 0.001 vs. vehicle, §P < 0.05, §§P < 0.01 vs. liraglutide (400 μg/kg). All data are means ± SEMCC BY · PubMed Central
Fig. 3 Oral glucose tolerance test (OGTT) after 4 and 8 weeks of treatment. The incremental area under the curve (iAUC) shown for blood glucose (a and c) and plasma insulin (b and d) during OGTT after 4 and 8 weeks, respectively. n = 8–10 rats per group. Statistical analysis between groups were performed as a one-way ANONA followed by Tukey’s post-hoc test (c) and as Kruskal Wallis test followed by Dunn’s post-hoc test (a, b, d) with the following annotations: *P < 0.05, **P < 0.01, ***P < 0.001 vs. vehicle, #P < 0.05, ##P < 0.01 vs. liraglutide (200 μg/kg), §P < 0.05, §§P < 0.01 vs. liraglutide (400 μg/kg), ¤ P < 0.05 vs. KBP-089 (0.625 μg/kg). All data are means ± SEM
Fig. 3 Oral glucose tolerance test (OGTT) after 4 and 8 weeks of treatment. The incremental area under the curve (iAUC) shown for blood glucose (a and c) and plasma insulin (b and d) during OGTT after 4 and 8 weeks, respectively. n = 8–10 rats per group. Statistical analysis between groups were performed as a one-way ANONA followed by Tukey’s post-hoc test (c) and as Kruskal Wallis test followed by Dunn’s post-hoc test (a, b, d) with the following annotations: *P < 0.05, **P < 0.01, ***P < 0.001 vs. vehicle, #P < 0.05, ##P < 0.01 vs. liraglutide (200 μg/kg), §P < 0.05, §§P < 0.01 vs. liraglutide (400 μg/kg), ¤ P < 0.05 vs. KBP-089 (0.625 μg/kg). All data are means ± SEMCC BY · PubMed Central
Fig. 4 Fasting plasma glucagon levels (a) and plasma glucagon levels during OGTT after 8 weeks of treatment (b). n = 8–10 rats per group. Statistical analysis between groups were performed as a one-way ANONA followed by Tukey’s post-hoc test. All data are means ± SEM
Fig. 4 Fasting plasma glucagon levels (a) and plasma glucagon levels during OGTT after 8 weeks of treatment (b). n = 8–10 rats per group. Statistical analysis between groups were performed as a one-way ANONA followed by Tukey’s post-hoc test. All data are means ± SEMCC BY · PubMed Central
Fig. 5 Gastric emptying after 4 (a) and 8 (b) weeks of treatment. Gastric emptying was estimated by the appearance of acetaminophen in plasma 30 min post dosing and calculated as % change relative vehicle. Statistical analysis between groups were performed as a one-way ANONA followed by Tukey’s post-hoc test with the following annotations: **P < 0.01, ***P < 0.001 vs. vehicle and §§§P < 0.001 vs. liraglutide (400 μg/kg). All data are means ± SEM
Fig. 5 Gastric emptying after 4 (a) and 8 (b) weeks of treatment. Gastric emptying was estimated by the appearance of acetaminophen in plasma 30 min post dosing and calculated as % change relative vehicle. Statistical analysis between groups were performed as a one-way ANONA followed by Tukey’s post-hoc test with the following annotations: **P < 0.01, ***P < 0.001 vs. vehicle and §§§P < 0.001 vs. liraglutide (400 μg/kg). All data are means ± SEMCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Cited by

See all 33

Metadata

Authors
Larsen, A. T., Gydesen, S., Sonne, N., Karsdal, M. A., & Henriksen, K.
Affiliations
Nordic Bioscience (Denmark) (DK)
Corresponding author
Henriksen, Kim
Venue
BMC Endocrine Disorders
Published
2021-01-07
Volume
21
Issue
1
Pages
10-10
ISSN
1472-6823 (ISSN-L)
OpenAlex
W3119986206
Cited by
33
References
45
Citations by year
2026: 7 · 2025: 5 · 2024: 8 · 2023: 6 · 2022: 3 · 2021: 4
FWCI
2.76
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Endocrine Disorders (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Den Danske Forskningsfond (N/A)
Topics
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
liraglutide, amylin receptor agonist, GLP-1 receptor agonists, obesity treatment, weight loss, high-fat diet, gastric emptying, glucose tolerance, dietary intake, glucagon, insulin secretion, combination therapy
MeSH terms
Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Blood Glucose, Drug Therapy, Combination, Glucagon-Like Peptides, Glucose Tolerance Test, Hypoglycemic Agents, Male, Obesity, Weight Loss, Rats, Sprague-Dawley, Receptors, Calcitonin, Rats, Metabolome, Receptors, Islet Amyloid Polypeptide, Diet, High-Fat, Amylin Receptor Agonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile. https://app.cochat.ai/papers/10.1186/s12902-020-00678-2
The paper
Larsen, A. T., Gydesen, S., Sonne, N., Karsdal, M. A., & Henriksen, K. (2021). The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-020-00678-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.